MX2015017599A - Compuestos biciclicos utiles para el tratamiento de enfermedades causadas por retrovirus. - Google Patents
Compuestos biciclicos utiles para el tratamiento de enfermedades causadas por retrovirus.Info
- Publication number
- MX2015017599A MX2015017599A MX2015017599A MX2015017599A MX2015017599A MX 2015017599 A MX2015017599 A MX 2015017599A MX 2015017599 A MX2015017599 A MX 2015017599A MX 2015017599 A MX2015017599 A MX 2015017599A MX 2015017599 A MX2015017599 A MX 2015017599A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- retroviral infection
- treating
- preventing
- disease caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe en la presente métodos para prevenir o tratar una infección retrovírica y/o para prevenir, inhibir o tratar una enfermedad causada por la infección retrovírica. En ciertos aspectos, los métodos descritos en la presente incluyen poner en contacto una célula que necesita del mismo con el compuesto (1) (ver Fórmula) en donde: (ver Fórmula) significa a grupo piridazina, pirimidina o pirazina, R representa independientemente un átomo de hidrógeno, un átomo de halógeno o un grupo elegido de entre un grupo - CN, un grupo hidroxilo, un grupo -COOR1, un grupo fluoroalquilo(C1-C3), un grupo fluoroalcoxi(C1-C3), un grupo - NO2, un grupo -NR1R2, un grupo alcoxi (C1-C4), un grupo fenoxi y un grupo alquilo (C1-C3), el alquilo siendo opcionalmente mono-sustituido por un grupo hidroxilo, n es 1, 2 o 3, n´ es 1 o 2, R´ es un átomo de hidrógeno, un átomo de halógeno o un grupo elegido de entre un grupo alquilo (C1-C3), , un grupo hidroxilo, un grupo -COOR1, un grupo -NO2, un grupo -NR1R2, un grupo morfolinilo o uno morfolino, un grupo N-metilpiperazinilo, un grupo fluoroalquilo(C1-C3), un grupo alcoxi(C1-C4) y un grupo -CN, Z es N o C, Y es N o C, X es N o C, W es N o C, T es N o C, U es N o C, Para prevenir o tratar la infección retrovírica y/o para prevenir, inhibir o tratar una enfermedad causada por la infección retrovírica, en donde la infección retrovírica no es VIH y la enfermedad causada por infección retrovírica que no es SIDA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843155P | 2013-07-05 | 2013-07-05 | |
PCT/IB2014/062849 WO2015001518A1 (en) | 2013-07-05 | 2014-07-04 | Bicyclic compounds useful for treating diseases caused by retroviruses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015017599A true MX2015017599A (es) | 2016-04-07 |
Family
ID=51453778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015017599A MX2015017599A (es) | 2013-07-05 | 2014-07-04 | Compuestos biciclicos utiles para el tratamiento de enfermedades causadas por retrovirus. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9827237B2 (es) |
EP (1) | EP3016656B1 (es) |
JP (2) | JP6895251B2 (es) |
KR (1) | KR102326068B1 (es) |
CN (1) | CN105530938B (es) |
AU (1) | AU2014285733B2 (es) |
BR (1) | BR112016000127B1 (es) |
CA (1) | CA2916623C (es) |
ES (1) | ES2898385T3 (es) |
HK (1) | HK1217447A1 (es) |
HR (1) | HRP20211839T1 (es) |
MX (1) | MX2015017599A (es) |
PL (1) | PL3016656T3 (es) |
PT (1) | PT3016656T (es) |
RU (1) | RU2681943C9 (es) |
WO (1) | WO2015001518A1 (es) |
ZA (1) | ZA201600317B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
EP3059236A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | A new quinoline derivative for use in the treatment and prevention of viral infections |
EP3058940A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Quinoline derivatives for use in the treatment or prevention of viral infection |
EP3059591A1 (en) * | 2015-02-23 | 2016-08-24 | Abivax | Methods for screening compounds for treating or preventing a viral infection or a virus-related condition |
KR20170109160A (ko) | 2016-03-18 | 2017-09-28 | 현대자동차주식회사 | 엔진마운트의 체결구조 |
DK3484528T3 (da) | 2016-07-18 | 2021-02-15 | Janssen Pharmaceutica Nv | Tau-pet-billeddannelsesligander |
EP3594205A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
EP3594206A1 (en) * | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
EP3848356A1 (en) * | 2020-01-07 | 2021-07-14 | Abivax | Aryl-n-aryl derivatives for treating a rna virus infection |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
AU2022283404A1 (en) | 2021-05-27 | 2023-11-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals |
CN116120282B (zh) * | 2022-08-04 | 2024-02-20 | 苏州***医学研究所 | 具有ev71和/或cva16病毒抑制活性的化合物及其应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB585362A (en) | 1944-08-31 | 1947-02-05 | Francis Henry Swinden Curd | New heterocyclic compounds |
BE486034A (es) | 1947-11-28 | |||
DE958647C (de) | 1952-12-28 | 1957-02-21 | Hoechst Ag | Verfahren zur Herstellung von 7-Amino-2-oxy-4-methyl-chinolinen |
FR2387229A1 (fr) | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
FR2436786A1 (fr) | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
FR2627493B1 (fr) | 1988-02-23 | 1991-10-31 | Sanofi Sa | Procede de preparation de derives d'isoquinoleine |
FR2645861A1 (fr) | 1989-04-17 | 1990-10-19 | Inst Nat Sante Rech Med | Utilisation de dipyrido (4,3-b) (3,4-f) indoles pour la preparation de medicaments utiles pour le traitement du sida |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US6337350B1 (en) | 1999-04-05 | 2002-01-08 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGEs) |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
DE10013318A1 (de) | 2000-03-17 | 2001-09-20 | Merck Patent Gmbh | Formulierung enthaltend Chinoxalinderivate |
AU2002303078B2 (en) | 2001-01-22 | 2007-08-30 | Memory Pharmaceuticals Corporation | Aniline derivatives useful as phosphodiesterase 4 inhibitors |
EP1542692B1 (en) | 2002-05-22 | 2011-01-05 | Amgen Inc. | Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
WO2004009552A1 (en) | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
FR2849474B3 (fr) | 2002-12-27 | 2004-12-03 | Olivier Jean Noel Juin | Installation de transformation de l'energie cinetique d'un fluide en energie electrique |
WO2004078731A1 (fr) | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
FR2859474B1 (fr) | 2003-09-04 | 2006-01-13 | Centre Nat Rech Scient | Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
FR2859475A1 (fr) | 2003-09-04 | 2005-03-11 | Centre Nat Rech Scient | Utilisation de composes derives d'ellipticine et d'aza-ellipticine pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage |
DE602004031037D1 (de) | 2003-11-19 | 2011-02-24 | Array Biopharma Inc | Heterocyclische inhibitoren von mek |
EP1853265B1 (en) | 2005-01-28 | 2016-01-27 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Farnesyltransferase inhibitors for use in the treatment of laminopathies, cellular aging and atherosclerosis |
FR2903312B1 (fr) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament |
US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
CN101663279A (zh) | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | Mek抑制剂 |
FR2912745A1 (fr) | 2007-02-19 | 2008-08-22 | Centre Nat Rech Scient | Nouveaux composes derives d'indole et compositions pharmaceutiques les contenant |
US20100249184A1 (en) | 2007-03-16 | 2010-09-30 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
CN101679150B (zh) | 2007-05-17 | 2013-05-15 | Lg化学株式会社 | 蒽衍生物和使用该蒽衍生物的有机电子器件 |
AU2008286760A1 (en) | 2007-08-15 | 2009-02-19 | Memory Pharmaceuticals Corporation | 3' substituted compounds having 5-HT6 receptor affinity |
WO2009029617A1 (en) | 2007-08-27 | 2009-03-05 | Kalypsys, Inc. | Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors |
FR2926297B1 (fr) | 2008-01-10 | 2013-03-08 | Centre Nat Rech Scient | Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage. |
WO2010143169A2 (en) | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
EP2266972A1 (en) * | 2009-06-12 | 2010-12-29 | Splicos | New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies |
WO2010151755A2 (en) | 2009-06-25 | 2010-12-29 | The Brigham And Women's Hospital, Inc. | TREATMENT OF INFLAMMATORY DISEASES USING miR-124 |
EP2465502A1 (en) | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
CA2887066A1 (en) * | 2012-10-04 | 2014-04-10 | Oyagen, Inc. | Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof |
EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
-
2014
- 2014-07-04 AU AU2014285733A patent/AU2014285733B2/en active Active
- 2014-07-04 US US14/902,935 patent/US9827237B2/en active Active
- 2014-07-04 HR HRP20211839TT patent/HRP20211839T1/hr unknown
- 2014-07-04 MX MX2015017599A patent/MX2015017599A/es unknown
- 2014-07-04 JP JP2016522952A patent/JP6895251B2/ja active Active
- 2014-07-04 EP EP14758168.0A patent/EP3016656B1/en active Active
- 2014-07-04 CA CA2916623A patent/CA2916623C/en active Active
- 2014-07-04 PL PL14758168T patent/PL3016656T3/pl unknown
- 2014-07-04 CN CN201480038497.4A patent/CN105530938B/zh active Active
- 2014-07-04 WO PCT/IB2014/062849 patent/WO2015001518A1/en active Application Filing
- 2014-07-04 ES ES14758168T patent/ES2898385T3/es active Active
- 2014-07-04 BR BR112016000127-3A patent/BR112016000127B1/pt active IP Right Grant
- 2014-07-04 PT PT147581680T patent/PT3016656T/pt unknown
- 2014-07-04 RU RU2016103217A patent/RU2681943C9/ru active
- 2014-07-04 KR KR1020167003323A patent/KR102326068B1/ko active IP Right Grant
-
2016
- 2016-01-14 ZA ZA2016/00317A patent/ZA201600317B/en unknown
- 2016-05-16 HK HK16105584.3A patent/HK1217447A1/zh unknown
-
2019
- 2019-04-26 JP JP2019086240A patent/JP2019142946A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112016000127A8 (pt) | 2018-01-23 |
AU2014285733A1 (en) | 2016-01-21 |
CA2916623A1 (en) | 2015-01-08 |
JP6895251B2 (ja) | 2021-06-30 |
RU2681943C2 (ru) | 2019-03-14 |
KR20160032724A (ko) | 2016-03-24 |
AU2014285733B2 (en) | 2019-05-16 |
CN105530938B (zh) | 2019-10-22 |
EP3016656B1 (en) | 2021-09-08 |
KR102326068B1 (ko) | 2021-11-11 |
EP3016656A1 (en) | 2016-05-11 |
RU2681943C9 (ru) | 2019-05-16 |
WO2015001518A1 (en) | 2015-01-08 |
JP2019142946A (ja) | 2019-08-29 |
BR112016000127B1 (pt) | 2022-02-15 |
PT3016656T (pt) | 2021-11-26 |
ES2898385T3 (es) | 2022-03-07 |
RU2016103217A (ru) | 2017-08-10 |
HK1217447A1 (zh) | 2017-01-13 |
US20160151348A1 (en) | 2016-06-02 |
CN105530938A (zh) | 2016-04-27 |
CA2916623C (en) | 2021-09-14 |
ZA201600317B (en) | 2018-07-25 |
PL3016656T3 (pl) | 2022-02-21 |
JP2016523893A (ja) | 2016-08-12 |
HRP20211839T1 (hr) | 2022-03-04 |
US9827237B2 (en) | 2017-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015017599A (es) | Compuestos biciclicos utiles para el tratamiento de enfermedades causadas por retrovirus. | |
PH12018501716A1 (en) | Novel condensed pyrimidine compoun or salt thereof | |
MX359575B (es) | Compuestos utiles para tratar sida. | |
SG178591A1 (en) | Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer | |
PE20181449A1 (es) | Compuestos utiles como inhibidores de cinasa | |
NZ739893A (en) | Fused pyrimidine compound or salt thereof | |
BR112015022483A2 (pt) | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante | |
MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
NZ718055A (en) | Substituted pyrimidine bmi-1 inhibitors | |
MX2021006754A (es) | Derivados de quinoleina para el tratamiento de enfermedades inflamatorias. | |
BR112014014909A2 (pt) | agonistas de tgr5 não sistêmicos | |
EA201491456A1 (ru) | Соединения-ингибиторы raf | |
MX368162B (es) | Derivados de pirazolo[1,5-a]pirimidina sustituida con piperidina con actividad inhibidora sobre la replicacion del virus sincicial respiratorio (vsr). | |
MA38315B1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
NZ629411A (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
MX2019005934A (es) | Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). | |
MX2022000199A (es) | Compuesto de pirazolona y pirimidina, y metodo de preparacion y uso del mismo. | |
TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
MX2018013133A (es) | Compuesto de pirazolo[1,5-a]pirimidina. | |
MX2019008390A (es) | Compuestos utiles para tratar cancer. | |
WO2015110491A3 (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
CO2017001523A2 (es) | Novedosas pirimidinas 2,5-sustituidas | |
MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
EA201391396A1 (ru) | Макроциклические соединения и способы их получения |